Regulus Therapeutics Inc. (RGLS)

Check out top investors' recommendation for RGLS
Last closing price (Apr 23 4:00 EDT):
7.08 (-3.80%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
-11.61% ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of microRNA therapeutics to treat a range of diseases primarily in the United States. The company is developing various oligonucleotides, including miR-21 for hepatocellular carcinoma and for kidney fibrosis, miR-122 for hepatitis C virus infection, miR-33 for atherosclerosis, and miR-10b for glioblastoma multiforme treatment. It has strategic alliance with GlaxoSmithKline plc; and collaboration and license agreement with Sanofi, AstraZeneca, Alnylam and Isis, and Biogen Idec MA Inc. The company was founded in 2007 and is headquartered in San Diego, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
William Tanner Lazard Capital Markets Buy   Mar 05, '14   11.53    Mar 05, '15  -38.59% 
Alan Carr Needham & Company Buy   Feb 28, '14   11.23    Feb 28, '15  -36.95% 
Alan Carr Needham & Company Buy   Aug 14, '13   8.91  12.00  Aug 14, '14  -20.54% 
William Tanner Lazard Capital Markets Buy   Aug 14, '13   8.91  15.00  Aug 14, '14  -20.54% 
Jim Birchenough BMO Capital Markets Buy   Aug 14, '13   8.91    Aug 14, '14  -20.54% 
Enoch Kuo Unaffiliated Buy   Jul 17, '13   9.66  20.00  Jul 17, '14  -26.71% 
Alan Carr Needham & Company Buy   May 15, '13   7.29    May 15, '14  -2.88% 
William Tanner Lazard Capital Markets Buy   Oct 31, '12   4.78  14.00  Oct 31, '13  46.23%